Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy
NCT ID: NCT03885180
Last Updated: 2019-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
500 participants
INTERVENTIONAL
2019-03-20
2021-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy
NCT03280641
Dabigatran Versus Warfarin With NVAF Who Undergo PCI
NCT03536611
The Prevalence of Sub Optimal Anti Coagulation
NCT03485300
Genotype-guided Versus Standard for Warfarin Dosing
NCT03479684
Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients
NCT00356759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stop anticoagulation group
Just stop oral anticoagulation like routine
No interventions assigned to this group
Extend anticoagulation group
Extended the duration anticoauglation to 12 months
Warfarin Sodium
Extending warfarin anticoagulation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Warfarin Sodium
Extending warfarin anticoagulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Recently bleedings within 3 months
* Evaluated lifetime less than 2 years
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuhan Asia Heart Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Litao Zhang, MD
Head of anticoagulation clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wuhan Asia Heart Hospital
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-P-026
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.